Lupin Ltd. share price target

Background: Amongst the largest Pharma companies in domestic market with Net Sales of INR 112.9bn with a strong brand portfolio. R&D; cost is in excess of 8% of Sales. Exports account for 73% with Developed Markets (DM) at 58% and EM at 15%. Sales Mix: API - 10%, Domestic Formulations - 25%, DM Formulations - 56%, EM Formulations - 9%. Historically strong in anti-TB segment, has built expertise in fermentation based products and segments like...

Background: Amongst the largest Pharma companies in domestic market with Net Sales of INR 112.9bn with a strong brand portfolio. R&D; cost is in excess of 8% of Sales. Exports account for 73% with Developed Markets (DM) at 58% and EM at 15%. Sales Mix: API - 10%, Domestic Formulations - 25%, DM Formulations - 56%, EM Formulations - 9%. Historically strong in anti-TB segment, has built expertise in fermentation based products and segments like...

in domestic market w ith Net Sales of INR 112.9bn w ith a strong brand portfolio. R&D; cost is in excess of 8% of Sales. Exports account for 73% w ith Developed Markets ( DM) at 58% and EM at 15%. Sales Mix: A PI - 10%, Domestic For mulations - 25%, DM For mulations - 56%, EM For mulations - 9%. Historically strong in anti- TB segment, has built expertise in fer mentation based products and segments like...

About Laboratories Grin: Grin, incorporated in 1955, is a specialty pharmaceutical company engaged in manufacturing and commercialization of branded ophthalmic products. It posted sales of US$28mn in CY2013 and has ~275 employees (including 130 in direct field force). It owns a manufacturing and R&D; facility with marketing base in ~10 countries in Central and Latin America. Grin has ~80...

mar ket w ith Net Sales of INR 94.6bn w ith 230 brands. R&D; - 7.5% of Sales. Chronic, semi-chronic therapies account for 54%. FY07 - FY 12: Sales CA GR - 27%, PA T CA GR - 25%. Vertically integrated w ith strengths in manufacturing and IP based products.12 Mfg sites of w hich 2 in Japan. A PI sites -5, For mulation sites -7. 5 FDA inspected sites. Exports account for 70% of sales w ith US-38%, ROW-17%, Japan-12%, Europe-3% . For mulations- 90% of sales and A PI -10%. In US Generics account for 78%, branded for mulations-22%. Plans 120 launches in 3-4 y rs - addressable market...

mar ket w ith Net Sales of INR 94.6bn w ith 230 brands. R&D; - 7.5% of Sales. Chronic, semi-chronic therapies account for 54%. FY07 - FY 12: Sales CA GR - 27%, PA T CA GR - 25%. Vertically integrated w ith strengths in manufacturing and IP based products.12 Mfg sites of w hich 2 in Japan. A PI sites -5, For mulation sites -7. 5 FDA inspected sites. Exports account for 70% of sales w ith US-38%, ROW-17%, Japan-12%, Europe-3% . For mulations- 90% of sales and A PI -10%. In US Generics account for 78%, branded for mulations-22%. Plans 120 launches in 3-4 y rs - addressable market...

Background: Ranked 5th in domestic market with Net Sales of INR 94.6bn with 230 brands. R&D; - 7.5% of Sales. Chronic, semi-chronic therapies account for 54%. FY07 - FY 12: Sales CAGR - 27%, PAT CAGR - 25%. Vertically integrated with strengths in manufacturing and IP based products.12 Mfg sites of which 2 in Japan. API sites -5, Formulation sites -7. 5 FDA inspected sites. Exports account for 70% of sales with US-38%, ROW-17%, Japan-12%, Europe-3%. Formulations- 90% of sales and API -10%. In US Generics account for 78%, branded formulations-22%. Plans 120 launches in 3-4 yrs - addressable market...

Background: Ranked 5th in domestic market with Net Sales of INR 94.6bn with 230 brands. R&D; - 7.5% of Sales. Chronic, semi-chronic therapies account for 54%. FY07 - FY 12: Sales CAGR - 27%, PAT CAGR - 25%. Vertically integrated with strengths in manufacturing and IP based products.12 Mfg sites of which 2 in Japan. API sites -5, Formulation sites -7. 5 FDA inspected sites. Exports account for 70% of sales with US-38%, ROW-17%, Japan-12%, Europe-3%. Formulations- 90% of sales and API -10%. In US Generics account for 78%, branded formulations-22%. Plans 120 launches in 3-4 yrs - addressable market...

and developing markets of the world. It has grown to become the 14 largest generic pharmaceutical company in the world with a CAGR of 26% in Gross Sales, 30% in EBITDA and 31% in Net Profits for the last 7 years. It operates 10 world class manufacturing facilities...

Lupin Ltd is an India based pharmaceutical company, producing a range of generic and branded formulations and active pharmaceutical ingredients (APIs). The company offers various formulations in cephalosporins,...